EF Hutton Initiates Coverage On Anavex Life Sciences with Buy Rating, Announces Price Target of $46
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on Anavex Life Sciences (NASDAQ:AVXL) with a Buy rating and set a price target of $46.
July 22, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has initiated coverage on Anavex Life Sciences with a Buy rating and a price target of $46, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a high price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100